Skip to main content

Table 5 Prognostic factors. Cox regression analysis for patients' survival.

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

  Univariate Multivariate
  HR 95% CI P HR 95% CI P
Age       
< = 65 1 - -    
> 65 0.83 0.57-1.21 0.329    
Performance status       
0 1 - - 1 - -
1-2 1.96 1.32-2.90 0.001 1.89 1.25-2.88 0.003
Previous exposure to taxanes       
No 1 - -    
Yes 1.18 0.62-2.27 0.610    
Disease status       
Non-measurable 1 - -    
Measurable 1.49 0.88-2.55 0.141    
Platinum-free interval       
6-12 months 1 - - 1 - -
12.1-24 months 0.58 0.37-0.89 0.013 0.54 0.34-0.86 0.009
> 24 months 0.37 0.22-0.61 < 0.001 0.36 0.21-0.61 < 0.001
Randomization group       
A 1 - - 1 - -
B 1.15 0.78-1.66 0.455 1.19 0.80-1.76 0.399
  1. CI, confidence interval; HR, (Hazard Ratio)